Table 3.
Treatment-Related Adverse Events, n (%)
| Placebo | Trabodenoson | |||||
|---|---|---|---|---|---|---|
| Pooled (n = 59) | 50 mcg (n = 17) | 100 mcg (n = 17) | 200 mcg (n = 17) | 500 mcg (n = 34) | Pooled (n = 85) | |
| Eye disorders | ||||||
| Conjunctival hyperemia | 0 | 1 (5.9) | 1 (5.9) | 4 (23.5) | 6 (17.6) | 12 (14.1) |
| Ocular hyperemia | 0 | 0 | 2 (11.8) | 2 (11.8) | 0 | 4 (4.7) |
| Eyelid pruritis | 1 (1.7) | 0 | 0 | 1 (5.9) | 0 | 1 (1.2) |
| Eye irritation | 3 (5.1) | 0 | 0 | 0 | 0 | 0 |
| Foreign body sensation | 2 (3.4) | 0 | 0 | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Pruritus | 1 (1.7) | 0 | 0 | 0 | 0 | 0 |
| Nervous system disorders | ||||||
| Headache | 1 (1.7) | 0 | 0 | 0 | 0 | 0 |